Drug Profile
Tipapkinogene sovacivec - Transgene
Alternative Names: MVA-HPV-IL2 vaccine; R-3484; RG 3484; RO5217790; TG 4001Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Transgene
- Developer EMD Serono Research & Development Institute; Merck & Co; Roche; Transgene
- Class Antineoplastics; Cancer vaccines; Gene therapies; Immunotherapies; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Head and neck cancer; Oropharyngeal cancer
- Phase I/II Anal cancer; Cervical cancer; Penile cancer; Vulvovaginal cancer
- Discontinued Cervical intraepithelial neoplasia
Most Recent Events
- 05 Jun 2023 Efficacy data from a phase II trial in Anogenital cancer released by Transgene
- 02 Jun 2023 Efficacy and immunogenicity data from phase-Ib/II trial in Anal cancer, Penile cancer, Vulvovaginal cancer and Cervical cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 20 Mar 2023 Transgene plans a registrational clinical trial in HPV-positive cancer